TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity

Rory M. Shallis; Naval G. Daver; Jessica K. Altman; Robert P. Hasserjian; Hagop M. Kantarjian; Uwe Platzbecker; Valeria Santini; Andrew H. Wei; David A. Sallman; Amer M. Zeidan

doi:10.1002/cncr.34535

TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity

Rory M. Shallis, Naval G. Daver, Jessica K. Altman, Robert P. Hasserjian, Hagop M. Kantarjian, Uwe Platzbecker, Valeria Santini, Andrew H. Wei, David A. Sallman, Amer M. Zeidan

Leukemia

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.

Original language	English (US)
Pages (from-to)	175-180
Number of pages	6
Journal	Cancer
Volume	129
Issue number	2
DOIs	https://doi.org/10.1002/cncr.34535
State	Published - Jan 15 2023

Keywords

acute myeloid leukemia (AML)
cutoff
excess blasts
myelodysplastic syndrome (MDS)
p53
TP53

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/cncr.34535

Cite this

@article{10ad651ea1a843b593d0e0cdb717a45d,

title = "TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity",

abstract = "TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.",

keywords = "acute myeloid leukemia (AML), cutoff, excess blasts, myelodysplastic syndrome (MDS), p53, TP53",

author = "Shallis, {Rory M.} and Daver, {Naval G.} and Altman, {Jessica K.} and Hasserjian, {Robert P.} and Kantarjian, {Hagop M.} and Uwe Platzbecker and Valeria Santini and Wei, {Andrew H.} and Sallman, {David A.} and Zeidan, {Amer M.}",

note = "Publisher Copyright: {\textcopyright} 2022 American Cancer Society.",

year = "2023",

month = jan,

day = "15",

doi = "10.1002/cncr.34535",

language = "English (US)",

volume = "129",

pages = "175--180",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity

AU - Shallis, Rory M.

AU - Daver, Naval G.

AU - Altman, Jessica K.

AU - Hasserjian, Robert P.

AU - Kantarjian, Hagop M.

AU - Platzbecker, Uwe

AU - Santini, Valeria

AU - Wei, Andrew H.

AU - Sallman, David A.

AU - Zeidan, Amer M.

PY - 2023/1/15

Y1 - 2023/1/15

N2 - TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.

AB - TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.

KW - acute myeloid leukemia (AML)

KW - cutoff

KW - excess blasts

KW - myelodysplastic syndrome (MDS)

KW - p53

KW - TP53

UR - http://www.scopus.com/inward/record.url?scp=85142256034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85142256034&partnerID=8YFLogxK

U2 - 10.1002/cncr.34535

DO - 10.1002/cncr.34535

M3 - Article

C2 - 36397669

AN - SCOPUS:85142256034

SN - 0008-543X

VL - 129

SP - 175

EP - 180

JO - Cancer

JF - Cancer

IS - 2

ER -

TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this